trial · primary record
Atezolizumab
Hereditary Leiomyomatosis and Renal Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 65 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Incidence of adverse events |
| Registry ID | NCT04981509 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:33.909Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04981509
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.